[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Chekerov R, Klaman I, Zafrakas M, Könsgen D, Mustea A, Petschke B, Lichtenegger W, Sehouli J, Dahl E: Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia; 2006 Jan;8(1):38-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy.
  • OBJECTIVE: The aim of this study was to evaluate the expression of topoisomerase IIalpha (TOP2A) in epithelial and stromal cells of ovarian cancer.
  • METHODS: TOP2A expression was analyzed prospectively in normal and tumor epithelial and adjacent stromal cells using quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) after laser microdissection (n = 38), RNA in situ hybridization (n = 13), and immunohistochemistry (n = 69).
  • RESULTS: TOP2A mRNA was detected by RNA in situ hybridization in all ovarian cancer samples, with stronger hybridization signals in tumor epithelial cells compared to adjacent stromal cells.
  • Very interestingly, specific change was found in recurrent ovarian cancer after platinum-based chemotherapy: TOP2A expression decreased in tumor epithelial cells of recurrent ovarian cancer compared to primary ovarian cancer (P = .056), whereas it increased in tumor-adjacent stromal cells in carboplatin-treated recurrent tumors compared to primary ovarian cancer (P = .023).
  • CONCLUSION: TOP2A mRNA and protein expression in ovarian cancer exhibits specific patterns in tumor epithelial and adjacent stromal cells, which are differentially modulated after platinum-based chemotherapy.
  • These data support the recently discovered importance of the stromal compartment in tumor progression and suggest that tumor stromal cells might be relevant to the development of chemotherapy resistance in ovarian cancer.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Drug Resistance, Neoplasm. Epithelial Cells / metabolism. Female. Humans. Lasers. Microdissection. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Stromal Cells / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1999 Jul 23;98(2):137-46 [10428026.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):257-74 [9748618.001]
  • [Cites] J Med Invest. 2005 Feb;52(1-2):41-8 [15751272.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):348-56 [15891995.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1254-60 [10728684.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):921-7 [10970695.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):666-72 [11041055.001]
  • [Cites] Curr Opin Genet Dev. 2001 Feb;11(1):54-9 [11163151.001]
  • [Cites] Pathobiology. 2000;68(4-5):209-14 [11279348.001]
  • [Cites] J Epidemiol Biostat. 2001;6(1):107-38 [11385772.001]
  • [Cites] Breast Cancer Res. 2001;3(4):224-9 [11434873.001]
  • [Cites] Int J Gynecol Cancer. 2001;11 Suppl 1:7-11 [11488996.001]
  • [Cites] Int J Gynecol Cancer. 2001;11 Suppl 1:52-6 [11489004.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):2925-32 [11712788.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):691-7 [11895897.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Zentralbl Gynakol. 2002 Mar;124(3):176-83 [12070798.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Nov;34(11):1401-14 [12200035.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1673-9 [12738720.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):764-72 [14566826.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1403-10 [14973057.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):887-95 [14984957.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):548-53 [14991576.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):19-31 [15034864.001]
  • [Cites] Obstet Gynecol. 1982 May;59(5):576-82 [7070728.001]
  • [Cites] J Cell Biol. 1986 Dec;103(6 Pt 2):2569-81 [3025219.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] NCI Monogr. 1987;(4):61-71 [2819733.001]
  • [Cites] Adv Cancer Res. 1988;50:159-96 [3287842.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(23):9431-5 [2556712.001]
  • [Cites] Cancer Res. 1991 Nov 1;51(21):5915-20 [1682037.001]
  • [Cites] Int J Cancer. 1996 Aug 7;67(4):479-84 [8759604.001]
  • [Cites] Nucleic Acids Res. 1996 Nov 15;24(22):4464-70 [8948636.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):275-88 [9748627.001]
  • [Cites] Gene. 1998 Oct 23;221(2):255-66 [9795238.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1329-33 [9809560.001]
  • [Cites] J Obstet Gynaecol Res. 1998 Dec;24(6):447-51 [10063241.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 1:43-50 [10219452.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3206-14 [10397267.001]
  • [Cites] J Histochem Cytochem. 1997 Feb;45(2):251-63 [9016314.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1050-5 [9448283.001]
  • [Cites] Mol Pathol. 1997 Oct;50(5):247-53 [9497914.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):139-54 [9748545.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • (PMID = 16533424.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC1584288
  •  go-up   go-down


2. Muller M, Dupre PF, Lucas B, Simon H, Malhaire JP, Guillemet C, Dessogne P, Pradier O: [Carcinosarcoma of the ovary]. J Gynecol Obstet Biol Reprod (Paris); 2007 Jun;36(4):399-402
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinosarcoma of the ovary].
  • Ovarian carcinosarcoma, also called malignant mixed mesodermal tumour, is a rare ovarian tumour representing less than two per cent of ovarian cancers.
  • Carcinosarcoma is an aggressive tumour, which associates some epithelial elements (carcinoma) with a stromal component (sarcoma).
  • This tumour can be found in the female genital tractus, mostly in the uterus.
  • There is no existing consensus concerning treatment.
  • Nevertheless, surgical treatment is paramount for the survival of patients.
  • Response rates to chemotherapy are about 20%.
  • [MeSH-major] Carcinosarcoma / diagnosis. Ovarian Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17408876.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


3. Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, Kotsuji F: Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer; 2004 May 10;109(6):926-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary.
  • We evaluated whether tracer FDG uptake, quantified as an SUV by PET in ovarian epithelial tumors, correlates with clinical stage, tumor grade, cell proliferation and glucose metabolism, all of which are biomarkers for response to chemotherapy, prognosis and overall survival in ovarian cancer patients.
  • Seventeen patients suspected of having ovarian cancer by physical examination, tumor marker analysis and anatomic imaging (such as sonography, CT and/or MRI) underwent whole-body FDG-PET within the 2 weeks prior to surgery.
  • Seventeen epithelial ovarian tumor specimens (13 malignant tumors, 5 at stage I, 2 at stage II, 6 at stage III; 2 borderline tumors; and 2 benign lesions) were available for pathologic evaluation.
  • Therefore, glucose consumption, as determined by analysis of SUVs in FDG-PET, may be a noninvasive biomarker for ovarian epithelial tumors.
  • [MeSH-major] Fluorodeoxyglucose F18 / pharmacokinetics. Ki-67 Antigen / metabolism. Monosaccharide Transport Proteins / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Radiopharmaceuticals / pharmacokinetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radionuclide imaging. Biomarkers, Tumor. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / radionuclide imaging. Cell Division. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / radionuclide imaging. Female. Glucose / metabolism. Glucose Transporter Type 1. Humans. Neoplasm Staging. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15027127.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Ki-67 Antigen; 0 / Monosaccharide Transport Proteins; 0 / Radiopharmaceuticals; 0 / SLC2A1 protein, human; 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose
  •  go-up   go-down


Advertisement
4. Guillem V, Poveda A: Germ cell tumours of the ovary. Clin Transl Oncol; 2007 Apr;9(4):237-43
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germ cell tumours of the ovary.
  • Germinal cell tumours represent only 2-5% of all cancers of the ovary.
  • However, the characteristics of the tumour and the patients have some special qualities as high rates of healing goes together with a strong desire to keep fertility intact because this condition occurs in female children and adolescent girls.
  • Neither the prognosis nor the treatment of these tumours is homogeneous; the low incidence is the reason it is hard to develop prospective studies for establishing prognostic factors and specific treatments.
  • The introduction of adjuvant chemotherapy into initial surgery has improved the prognosis of these patients.
  • The surgical treatment demands the application of the same principles seen in cytoreduction surgery of epithelial cancers of the ovary (maximum possible cytoreduction), though in many cases hysterectomy and double adnexectomy may be obviated.
  • In view of the rarity of these tumours, it is advisable to work within cooperative groups that may have subgroups for the treatment of rare tumours.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal. Ovarian Neoplasms
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor. Carcinoma, Embryonal / diagnosis. Carcinoma, Embryonal / drug therapy. Carcinoma, Embryonal / pathology. Child. Choriocarcinoma / diagnosis. Choriocarcinoma / drug therapy. Choriocarcinoma / pathology. Chorionic Gonadotropin, beta Subunit, Human. Dysgerminoma / diagnosis. Dysgerminoma / drug therapy. Dysgerminoma / pathology. Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / pathology. Female. Humans. Neoplasm Staging. Ovary / pathology. Prognosis. Randomized Controlled Trials as Topic. Teratoma / diagnosis. Teratoma / drug therapy. Teratoma / pathology. World Health Organization. alpha-Fetoproteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462976.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  • [Number-of-references] 49
  •  go-up   go-down


5. Xing D, Orsulic S: A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci U S A; 2005 May 10;102(19):6936-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance.
  • Cell lines and tumors with defined genetic alterations provide ideal systems in which to test the molecular mechanisms of tumor sensitivity to pathway-targeted therapy.
  • We have generated mouse ovarian epithelial tumor cell lines that contain various combinations of genetic alterations in the p53, c-myc, K-ras and Akt genes.
  • Using both in vitro and in vivo approaches, we investigated the effect of rapamycin on cell proliferation, tumor growth, and the accumulation of peritoneal ascites.
  • Tumors with alternative survival pathways may require the inactivation of multiple individual pathways for successful treatment.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10 [10883018.001]
  • [Cites] Oncogene. 2000 May 4;19(19):2324-30 [10822383.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2097-106 [11395387.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6680-6 [11426655.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10320-5 [11504907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9 [11504908.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10031-3 [11526226.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7426-9 [11606375.001]
  • [Cites] Gynecol Oncol. 2002 Jan;84(1):47-52 [11748975.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):53-62 [12086888.001]
  • [Cites] Genes Dev. 2002 Aug 15;16(16):2045-57 [12183360.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • [Cites] Gynecol Oncol. 2003 Jan;88(1 Pt 2):S16-21; discussion S22-4 [12586079.001]
  • [Cites] Cancer Cell. 2003 May;3(5):483-95 [12781366.001]
  • [Cites] J Cell Biol. 2003 Oct 27;163(2):315-26 [14568991.001]
  • [Cites] Cell. 1994 Jun 17;77(6):841-52 [7911739.001]
  • [Cites] Science. 1994 Aug 12;265(5174):966-70 [8052857.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):360-8 [7812969.001]
  • [Cites] Int J Cancer. 1995 Aug 22;64(4):280-5 [7657393.001]
  • [Cites] J Biol Chem. 1998 Jun 26;273(26):16621-9 [9632736.001]
  • [Cites] Nature. 2004 Mar 18;428(6980):332-7 [15029198.001]
  • [Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5853-7 [15208673.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Nov 12;324(2):471-80 [15474452.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):45643-51 [15337760.001]
  • [Cites] J Biol Chem. 1989 Nov 25;264(33):20017-24 [2584205.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9267-71 [1409633.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):276-80 [8261452.001]
  • [Cites] Virology. 1998 Sep 1;248(2):295-304 [9721238.001]
  • [Cites] Virology. 1998 Sep 1;248(2):305-11 [9721239.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1579-86 [9815846.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):99-102 [9916799.001]
  • [Cites] J Cell Physiol. 1999 Feb;178(2):235-46 [10048588.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(3):177-81 [10410879.001]
  • [Cites] Nat Med. 2004 Nov;10(11):1257-60 [15502845.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4181-7 [15304393.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4188-93 [15319277.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):567-76 [10675491.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):136-41 [11134523.001]
  • (PMID = 15860581.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA103924; United States / NCI NIH HHS / CA / 1R01CA103924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Vascular Endothelial Growth Factor A; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1087513
  •  go-up   go-down


6. de Vos FY, Nuver J, Willemse PH, van der Zee AG, Messerschmidt J, Burgerhof JG, de Vries EG, Gietema JA: Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage. Eur J Cancer; 2004 Mar;40(5):696-700
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage.
  • Male germ cell tumour patients treated with cisplatin-based chemotherapy frequently develop cardiovascular risk factors and disease, but sparse information is available about long-term complications of this type of chemotherapy in women.
  • We investigated the prevalence of cardiovascular risk factors and vascular damage in 21 women (median age 39 years; range 26-57 years) with an epithelial or germ cell tumour of the ovary cured by cisplatin-based chemotherapy after a median follow-up of 14 years (range 3-21 years).
  • A substantial portion of young female patients cured by cisplatin-based chemotherapy are likely to develop cardiovascular risk factors and signs of endothelial damage at an early stage.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cardiovascular Diseases / chemically induced. Cisplatin / adverse effects. Germinoma / drug therapy. Neoplasms, Glandular and Epithelial / drug therapy. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15010070.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97C5T2UQ7J / Cholesterol; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Tazi EM, Lalya I, Tazi MF, Ahellal Y, M'rabti H, Errihani H: Transitional cell carcinoma of the ovary: a rare case and review of literature. World J Surg Oncol; 2010;8:98
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the ovary: a rare case and review of literature.
  • INTRODUCTION: Transitional cell carcinoma (TCC) of the ovary is a rare, recently recognized, subtype of ovarian surface epithelial cancer.
  • Abdominal computed tomography showed a pelvic mass.
  • After surgery, the pathologic report of the right ovarian tumour was TCC, grade 3, stage IC.
  • The patient underwent 3 cycles of chemotherapy: carboplatin and paclitaxel.
  • She is regularly followed up and has been disease free for 10 months CONCLUSION: Transitional cell carcinoma (TCC) of the ovary is a rare subtype of epithelial ovarian cancer.
  • Surgical resection is the primary therapeutic approach, and patient outcomes after chemotherapy are better than for other types of ovarian cancers.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Hysterectomy / methods. Ovarian Neoplasms / diagnosis. Ovariectomy / methods
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biopsy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lymph Node Excision. Neoplasm Staging. Pelvis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):453-63 [15087664.001]
  • [Cites] Int J Gynecol Pathol. 1987;6(1):29-39 [3570630.001]
  • [Cites] Am J Clin Pathol. 1990 Apr;93(4):457-65 [2321577.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):195-9 [15790458.001]
  • [Cites] Am J Obstet Gynecol. 1993 Apr;168(4):1178-85; discussion 1185-7 [8475964.001]
  • [Cites] Gynecol Oncol. 1995 Nov;59(2):211-5 [7590475.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 1995 Nov;30(11):658-61 [8745489.001]
  • [Cites] Am J Obstet Gynecol. 1997 Jul;177(1):120-5 [9240594.001]
  • [Cites] Arch Pathol Lab Med. 2005 Feb;129(2):194-9 [15679420.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 1995 Mar;30(3):153-6 [7796648.001]
  • (PMID = 21073751.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2996384
  •  go-up   go-down


8. Marsden DE, Friedlander M, Hacker NF: Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol; 2000 Jul-Aug;19(1):11-9
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of epithelial ovarian carcinoma: a review.
  • Epithelial carcinoma of the ovary is the most lethal of gynaecological malignancies and it affects about one in 70 women in developed countries.
  • Over 75% of women with the disease have tumour spread beyond the pelvis at the time of diagnosis, and their treatment requires the appropriate use of surgery and chemotherapy.
  • The strategies used in the treatment of ovarian cancer are constantly evolving.
  • An overview of current treatment regimens and their evolution is provided, with particular emphasis on the interdependence of surgery and chemotherapy in the optimal management of the disease.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / surgery. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen / blood. Chemotherapy, Adjuvant. Female. Humans. Laparotomy. Lymph Node Excision. Neoplasm Recurrence, Local. Neoplasm Staging. Platinum Compounds / therapeutic use. Reoperation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10883019.001).
  • [ISSN] 8756-0437
  • [Journal-full-title] Seminars in surgical oncology
  • [ISO-abbreviation] Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Platinum Compounds
  • [Number-of-references] 127
  •  go-up   go-down


9. Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A: Medical therapy of advanced malignant epithelial tumours of the ovary. Forum (Genova); 2000 Oct-Dec;10(4):323-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical therapy of advanced malignant epithelial tumours of the ovary.
  • Despite improvements seen in median and overall survival using a combination of platinum-compounds and paclitaxel (PTX), long-term survival rates for patients with advanced epithelial ovarian carcinoma remain disappointing and ongoing efforts have aimed to develop more effective primary therapy.
  • In the early 1990Os the drug PTX was first tested in ovarian cancer.
  • The International Collaborative Ovarian Neoplasm Study (ICON)3 is the first and only trial comparing PTX plus carboplatin against carboplatin alone or a (non-taxane) CP-based control arm.
  • The results of ICON3, in accordance with GOG132 study, appear to contradict the earlier positive results seen for PTX and CP in the GOG-111 and OV10 trials and suggested that single agent carboplatin, CY-adriamycin-CP are safe and effective first-line treatments for women requiring chemotherapy for ovarian cancer.
  • A meta-analysis with individual patient data is warranted to better clarify the issue of PTX in the front line therapy of advanced ovarian cancer.
  • Salvage chemotherapy is often utilised in patients with advanced ovarian cancer, due to the high frequency of recurrent disease even after a clinical or pathological complete response after primary chemotherapy.
  • Main objectives of salvage chemotherapy include: i. improvement in quality of life and symptoms; ii. tumour load reduction and survival advantage; iii. evaluation of potentially active new drugs to be included in first-line.
  • However, the chances of response are directly related to the treatment-free interval, with a response rate nearly equivalent to that of primary chemotherapy when the treatment-free interval exceeds 24 months.
  • Extension of the platinum-free interval before re-treatment with platinum or taxanes may allow partial reversal of resistance to these agents which can therefore still show significant activity in relapsing patients.
  • Unfortunately, durable response to salvage chemotherapy is rare and cure is almost impossible.
  • The sequential use of the agents currently available for salvage treatment in monotherapy may transform ovarian cancer into a chronic disease and confers long survival to the patients.
  • Perhaps, the most interesting role of second-line chemotherapy is to identify new potentially active drugs, which can be moved up-front.
  • Most of the compounds used in second line (gemcitabine, topotecan, liposomal doxorubicin) are in fact under investigation to develop alternative schedules and sequences of drug administration.
  • A new phase III multi-national randomised study for patients with advanced stage epithelial ovarian or primary periperitoneal carcinoma will evaluate the impact of incorporating a new drug within either a platinum-based triplet (new drug + platinum + PTX) or a sequential-doublet (new drug + platinum followed by platinum + PTX) in order to identify one or more experimental regimens able to improve long-term survival with acceptable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Resistance, Neoplasm. Female. Humans. Neoplasm Staging. Paclitaxel / administration & dosage. Palliative Care / methods. Palliative Care / standards. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11535983.001).
  • [ISSN] 1121-8142
  • [Journal-full-title] Forum (Genoa, Italy)
  • [ISO-abbreviation] Forum (Genova)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 48
  •  go-up   go-down


10. Roger N, Zafrani Y, Uzan C, Gouy S, Rey A, Pautier P, Lhommé C, Duvillard P, Castaigne D, Morice P: Should pelvic and para-aortic lymphadenectomy be different depending on histological subtype in epithelial ovarian cancer? Ann Surg Oncol; 2008 Jan;15(1):333-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should pelvic and para-aortic lymphadenectomy be different depending on histological subtype in epithelial ovarian cancer?
  • BACKGROUND: The aim of this study was to determine the influence of the different histological subtypes (serous versus non-serous) on the location of nodal metastases in patients undergoing pelvic and para-aortic lymphadenectomies during the initial management of epithelial ovarian tumors.
  • (1) an epithelial ovarian tumor;.
  • (3) surgical procedures including lymphadenectomies performed before adjuvant chemotherapy; and (4) a description of the distribution of positive nodes removed between pelvic and para-aortic areas.
  • RESULTS: Of patients treated between 1989 and 2005, 148 fulfilled the inclusion criteria: 73 had a serous tumor and 75 a non-serous tumor.
  • CONCLUSIONS: This series suggests that the histological subtype has no impact on the distribution of positive nodes in pelvic and para-aortic areas in patients with epithelial ovarian tumors.
  • [MeSH-major] Cystadenocarcinoma, Serous / secondary. Lymph Node Excision. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aorta. Carcinoma, Endometrioid / secondary. Carcinoma, Endometrioid / surgery. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Para-Aortic Bodies. Pelvis. Prognosis. Retrospective Studies


11. D'Angelo E, Prat J: Classification of ovarian carcinomas based on pathology and molecular genetics. Clin Transl Oncol; 2010 Dec;12(12):783-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of ovarian carcinomas based on pathology and molecular genetics.
  • Malignant epithelial tumours (carcinomas) are the most common ovarian cancers and the most lethal gynaecological malignancies.
  • Based on light microscopy and molecular genetics, ovarian carcinomas are subdivided into at least five main subtypes that account for over 95% of cases and are inherently different diseases, as indicated by differences in epidemiological and genetic risk factors, precursor lesions, patterns of spread, molecular events during oncogenesis, response to chemotherapy and outcome.
  • For successful subtype-specific treatment, reproducible pathological diagnosis of tumour cell type is critical.
  • Recent investigations have also demonstrated that a significant number of cancers traditionally thought to be primary ovarian tumours (particularly serous, endometrioid and clear cell carcinomas) originate in the fallopian tube and the endometrium and involve the ovary secondarily.
  • In this review we summarise recent advances in the molecular pathology, which have greatly improved our understanding of the biology of ovarian carcinoma and are also relevant to patient management.
  • [MeSH-major] Ovarian Neoplasms / classification. Ovary / pathology
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Female. Humans. Neoplasms, Glandular and Epithelial / classification. Neoplasms, Glandular and Epithelial / genetics. Neoplasms, Glandular and Epithelial / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2004 Feb;44(2):109-15 [14764054.001]
  • [Cites] Cancer Res. 1998 May 15;58(10 ):2095-7 [9605750.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):605-19 [16021566.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):564-9 [10749912.001]
  • [Cites] BMC Cancer. 2008 Jan 22;8:17 [18208621.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):342-6 [10053105.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1040-4 [15020606.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1581-6 [9118042.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1078-85 [12454811.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):139-52 [11812936.001]
  • [Cites] Hum Pathol. 2004 Nov;35(11):1360-8 [15668893.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7052-6 [11156411.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Obstet Gynecol. 2002 Jan;99(1):3-10 [11777502.001]
  • [Cites] Gynecol Oncol. 2007 Dec;107(3):469-73 [17765295.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):147-59 [15043303.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1344-7 [9537226.001]
  • [Cites] Obstet Gynecol. 2002 Aug;100(2):281-7 [12151151.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):917-21 [15829967.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Obstet Gynecol. 2006 Aug;108(2):361-8 [16880307.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):496-504 [15087669.001]
  • [Cites] Hum Pathol. 2009 Sep;40(9):1213-23 [19552940.001]
  • [Cites] J Pathol. 2007 Feb;211(3):286-95 [17154249.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • (PMID = 21156408.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Ovarian epithelial cancer
  •  go-up   go-down


12. Sharma S, Qian F, Keitz B, Driscoll D, Scanlan MJ, Skipper J, Rodabaugh K, Lele S, Old LJ, Odunsi K: A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. Gynecol Oncol; 2005 Oct;99(1):183-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer.
  • OBJECTIVES: Cancer-testis (CT) antigens are expressed in tumors but not normal tissues except the testis and could be targets for vaccine therapy in epithelial ovarian cancer (EOC).
  • METHODS: One step RT-PCR was performed with RNA from normal and ovarian cancer cell lines and 74 epithelial ovarian tumor tissues.
  • RESULTS: AKAP-3 mRNA expression was demonstrated in 43/74 (58%) of the ovarian cancer specimens.
  • AKAP-3 was expressed in normal testis, but not in other normal tissues.
  • AKAP-3 expression significantly correlated with increased likelihood of residual tumor (P = 0.005), but no increase in the likelihood of recurrence or persistent disease (P = 0.06).
  • Multivariate analysis of AKAP-3 expression, residual disease, and response to frontline chemotherapy found response to be the strongest predictor of overall survival (P = 0.012).
  • Since AKAP-3 demonstrates tumor-restricted expression and appears to be associated with worse overall survival, it could represent an attractive target for antigen-specific immunotherapy in EOC.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Ovarian Neoplasms / genetics. RNA, Messenger / biosynthesis
  • [MeSH-minor] A Kinase Anchor Proteins. Adult. Aged. Aged, 80 and over. Epithelial Cells / pathology. Female. Humans. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16005946.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / A Kinase Anchor Proteins; 0 / AKAP3 protein, human; 0 / Adaptor Proteins, Signal Transducing; 0 / RNA, Messenger
  •  go-up   go-down


13. Maubant S, Cruet-Hennequart S, Dutoit S, Denoux Y, Crouet H, Henry-Amar M, Gauduchon P: Expression of alpha V-associated integrin beta subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinum-based regimens. J Mol Histol; 2005 Feb;36(1-2):119-29
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of alpha V-associated integrin beta subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinum-based regimens.
  • The aim of the study was to investigate the relationships between the expression of alphav, beta1, beta3, beta5, and beta6, integrin subunits and clinical parameters in ovarian cancers.
  • Ovarian surface epithelium (OSE) from five donors and tumour samples from 39 patients with an epithelial ovarian cancer (39 primary tumours and 21 associated peritoneal metastases) were analysed using immunohistochemistry on paraffin-embedded or frozen tissue sections.
  • Survival analyses restricted to patients receiving platinum-based chemotherapy did not reveal any relationship between integrin subunit expression and 3-year survival rate, in this limited series of patients.
  • In conclusion, the expression of the various beta integrin subunits was differentially altered in ovarian carcinoma, evocative of complementary roles of alphav integrins during tumour development.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / drug therapy. Integrin alphaV / metabolism. Integrin beta Chains / metabolism. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Humans. Middle Aged. Neoplasm Staging. Ovary / chemistry. Platinum Compounds / therapeutic use. Prognosis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):260-7 [8751559.001]
  • [Cites] J Histochem Cytochem. 2002 Oct;50(10):1371-80 [12364570.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):397-414 [15277215.001]
  • [Cites] Gynecol Oncol. 1995 Aug;58(2):216-25 [7542622.001]
  • [Cites] J Biol Chem. 1990 Jul 5;265(19):11008-13 [1694173.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):248-57 [12893184.001]
  • [Cites] Cancer Surv. 1995;24:113-27 [7553657.001]
  • [Cites] J Cell Sci. 1998 Aug;111 ( Pt 15):2189-95 [9664040.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]
  • [Cites] J Biol Chem. 1990 Apr 15;265(11):5934-7 [2138612.001]
  • [Cites] Biol Chem. 2003 Jul;384(7):1073-83 [12956424.001]
  • [Cites] Carcinogenesis. 2002 Feb;23(2):237-44 [11872628.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):281-304 [9633841.001]
  • [Cites] Curr Opin Cell Biol. 1996 Oct;8(5):724-30 [8939661.001]
  • [Cites] Hum Pathol. 1997 Apr;28(4):443-9 [9104944.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1587-94 [10389948.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7084-93 [11156415.001]
  • [Cites] J Cell Sci. 1993 May;105 ( Pt 1):101-11 [7689573.001]
  • [Cites] Cell. 2002 Sep 20;110(6):673-87 [12297042.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):369-76 [9219848.001]
  • [Cites] Anticancer Res. 2001 May-Jun;21(3C):2185-8 [11501844.001]
  • [Cites] Cell Mol Life Sci. 1998 Jun;54(6):541-8 [9676573.001]
  • [Cites] Nat Med. 1999 Jun;5(6):662-8 [10371505.001]
  • [Cites] Int J Biochem Cell Biol. 2000 Feb;32(2):171-88 [10687952.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):261-7 [8486429.001]
  • [Cites] J Cell Biol. 1994 Oct;127(2):547-56 [7929593.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4073-9 [11751504.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):186-94 [11774263.001]
  • [Cites] J Oral Pathol Med. 1997 Feb;26(2):63-8 [9049904.001]
  • [Cites] Am J Pathol. 1996 May;148(5):1445-61 [8623916.001]
  • [Cites] Nat Cell Biol. 2002 Apr;4(4):E65-8 [11944032.001]
  • [Cites] J Biol Chem. 1994 Mar 4;269(9):6940-8 [8120056.001]
  • [Cites] Cell. 1992 Apr 3;69(1):11-25 [1555235.001]
  • [Cites] Oncogene. 2003 Mar 20;22(11):1688-702 [12642872.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):362-7 [10366461.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):285-94 [9935212.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(13 Spec No):1607-20 [10959047.001]
  • [Cites] Anticancer Res. 1993 Jan-Feb;13(1):1-11 [8476198.001]
  • (PMID = 15704006.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Integrin alphaV; 0 / Integrin beta Chains; 0 / Platinum Compounds
  •  go-up   go-down


14. Buda A, Dell'Anna T, Signorelli M, Mangioni C: Role of ifosfamide in cervical cancer: an overview. Oncology; 2003;65 Suppl 2:63-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ifosfamide, a cyclophosphamide analogue, has demonstrated a wide spectrum of activity against numerous neoplasms in different oncologic areas, including paediatric, haematological, breast, lung and testicular cancers, soft tissue sarcomas and gynaecological cancer.
  • In gynaecologic cancers in particular, evidence suggests activity in the treatment of epithelial ovarian cancer, cervical carcinoma, germ cell carcinoma of the ovary.
  • Cervical cancer has long been considered a poorly chemosensitive tumour and for several years the role of chemotherapy in the treatment of this tumour was confined to persistent or recurrent disease after failure of surgery and/or radiotherapy.
  • In the management of cervical cancer, chemotherapy has received increasing attention in the last two decades and is currently used in neoadjuvant regimens, as salvage treatment in patients with disseminated or recurrent disease, or as a radiosensitizer.
  • Cisplatin represents the cornerstone of chemotherapy for cervical cancer.
  • Ifosfamide has been studied as a single agent or in combination with other drugs in different studies.
  • In this paper we reviewed the approach with systemic therapy and, in particular, the role of ifosfamide in advanced or recurrent, and less advanced cervical cancer.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Ifosfamide / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy


15. Geetha P, Nair MK: Granulosa cell tumours of the ovary. Aust N Z J Obstet Gynaecol; 2010 Jun;50(3):216-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulosa cell tumours of the ovary.
  • Granulosa cell tumours are rare, potentially malignant sex cord stromal tumours of the ovary.
  • Many of them are hormone-producing and this property helps them to present early unlike other epithelial ovarian cancers.
  • As a result, most of them will be in an early stage at the time of initial diagnosis.
  • The tumour can manifest in young girls as a juvenile form and conservative management with unilateral salpingo-opherectomy may be an option in them as 95% are unilateral.
  • Surgery is the treatment of choice and initial staging laparatomy a determinant recurrence.
  • Advance stage of the tumour, its size (>5 cm), mitotic figures (>10/hpf), nuclear atypia and absence of call-exner bodies are poor prognostic factors.
  • Tumour markers such as inhibin and estradiol are useful in follow-up.
  • Chemotherapy, radiotherapy and hormone replacement therapy have very little role in the initial treatment and may be suggested in case of recurrences.
  • With appropriate treatment, a better survival rate can be achieved as against other ovarian malignancies.
  • [MeSH-major] Granulosa Cell Tumor / diagnosis. Granulosa Cell Tumor / therapy. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20618236.001).
  • [ISSN] 1479-828X
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


16. Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP: Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology; 2008 Aug;53(2):127-38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective.
  • Prolongation of ovarian epithelial cancer survival depends on early detection or improved responses to chemotherapy.
  • This review proposes two distinct pathways to pelvic epithelial cancer.
  • The first initiates in ovarian surface epithelium (OSE), Mullerian inclusions or endometriosis in the ovary.
  • The serous carcinogenic sequence in the distal fallopian tube is described and contrasted with lower grade serous tumors based on tumour location, earliest genetic change and ability (or lack of) to undergo terminal (ciliated) differentiation.
  • Ultimately, a clear understanding of tumour origin and the mechanism(s) leading to the earliest phases of the serous and endometrioid carcinogenic sequences may hold the greatest promise for designing prevention strategies and/or developing new therapies.
  • [MeSH-major] Fallopian Tube Neoplasms / etiology. Fallopian Tube Neoplasms / pathology. Neoplasms, Glandular and Epithelial / etiology. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / etiology. Ovarian Neoplasms / pathology. Pelvic Neoplasms / etiology. Pelvic Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2009 Mar;54(4):494-5 [19309405.001]
  • (PMID = 18298580.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R21 CA124688; United States / NCI NIH HHS / CA / 1P50CA 105009; United States / NCI NIH HHS / CA / K08 CA108748
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 52
  •  go-up   go-down


17. Lindboe CF: Large cell neuroendocrine carcinoma of the ovary. APMIS; 2007 Feb;115(2):169-76
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell neuroendocrine carcinoma of the ovary.
  • Large cell neuroendocrine carcinoma of the ovary is a recently described tumour entity that is now included in the WHO classification of primary ovarian neoplasms.
  • Although mostly in stage I at diagnosis, this tumour shows an aggressive clinical behaviour with subsequent metastases and mean survival is less than one year.
  • In addition to the neuroendocrine carcinoma, most cases also have a malignant surface epithelial tumour component.
  • I here report a 64-year-old woman who was operated on for a right-sided ovarian large cell neuroendocrine carcinoma without a surface epithelial component, which constitutes only the second reported tumour of this "pure" kind.
  • The patient was treated postoperatively with chemotherapy.
  • She developed bleomycin-induced lung fibrosis that responded well to treatment with steroids.
  • There have been no signs of local tumour recurrence or metastases at follow-up examinations during the first 9 months after the operation.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, Neoplasm / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17295684.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


18. Zhou H, Luo MP, Schönthal AH, Pike MC, Stallcup MR, Blumenthal M, Zheng W, Dubeau L: Effect of reproductive hormones on ovarian epithelial tumors: I. Effect on cell cycle activity. Cancer Biol Ther; 2002 May-Jun;1(3):300-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of reproductive hormones on ovarian epithelial tumors: I. Effect on cell cycle activity.
  • We examined the effects of the 4 major female reproductive hormones, estradiol (E2), progesterone (P4), follicle stimulating hormone (FSH), and luteinizing hormone (LH) on thymidine incorporation in benign and malignant ovarian epithelial tumors cultured in vitro.
  • Treatment of these tumors with E2, FSH and LH resulted in increased thymidine incorporation while treatment with P4 inhibited growth as well as thymidine incorporation.
  • Expression of a reporter gene downstream to an AP-1 responsive element in a plasmid construct transfected into ovarian epithelial tumor cells was induced by P4 and inhibited by RU486.
  • We conclude that P4 inhibits cell cycle activity in ovarian epithelial tumors, in part via down-regulation of the cdkl/cyclin B complex.
  • This inhibitory effect may have therapeutic utility against ovarian epithelial tumors.
  • [MeSH-major] Cell Cycle / drug effects. Cell Cycle Proteins / metabolism. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / pathology. Tumor Cells, Cultured / pathology
  • [MeSH-minor] Cell Division / drug effects. DNA, Neoplasm / metabolism. Down-Regulation. Estradiol / pharmacology. Female. Follicle Stimulating Hormone / pharmacology. Gonadal Steroid Hormones / pharmacology. Humans. Ligands. Luteinizing Hormone / pharmacology. Progesterone / pharmacology. Receptors, Glucocorticoid / agonists. Receptors, Mineralocorticoid / agonists. Receptors, Progesterone / agonists. Thymidine / metabolism. Transcription Factor AP-1 / genetics. Transcription Factor AP-1 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12432283.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5P30 CA14089-21; United States / NCI NIH HHS / CA / R01 CA 51167; United States / NCI NIH HHS / CA / R01 CA 79750; United States / NIDDK NIH HHS / DK / R01DK43093
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / Gonadal Steroid Hormones; 0 / Ligands; 0 / Receptors, Glucocorticoid; 0 / Receptors, Mineralocorticoid; 0 / Receptors, Progesterone; 0 / Transcription Factor AP-1; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; VC2W18DGKR / Thymidine
  •  go-up   go-down


19. Hafezi-Bakhtiari S, Morava-Protzner I, Burnell MJ, Reardon E, Colgan TJ: Choriocarcinoma arising in a serous carcinoma of ovary: an example of histopathology driving treatment. J Obstet Gynaecol Can; 2010 Jul;32(7):698-702
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choriocarcinoma arising in a serous carcinoma of ovary: an example of histopathology driving treatment.
  • BACKGROUND: Choriocarcinoma within an ovarian carcinoma is exceptionally rare.
  • Nevertheless, recognition of this mixed tumour is important for administration of appropriate chemotherapy.
  • CASE: A 65-year-old woman underwent resection of an ovarian mass after presenting with a pelvic mass and breast tenderness.
  • This pathologic diagnosis led to a specific chemotherapy regimen with cisplatin, etoposide, and bleomycin, suitable for both types of malignancy.
  • CONCLUSION: Both gynaecologists and pathologists should be aware that the histopathologic classification of ovarian epithelial carcinoma and its variants, such as this one, may have an increasing role in the management of this disease.
  • [MeSH-major] Choriocarcinoma / pathology. Cystadenocarcinoma, Serous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20707961.001).
  • [ISSN] 1701-2163
  • [Journal-full-title] Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC
  • [ISO-abbreviation] J Obstet Gynaecol Can
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


20. La Marca A, Volpe A: The Anti-Mullerian hormone and ovarian cancer. Hum Reprod Update; 2007 May-Jun;13(3):265-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Anti-Mullerian hormone and ovarian cancer.
  • Ovarian granulosa cells also secrete AMH from late in fetal life.
  • The patterns of expression of AMH and its type II receptor in the post-natal ovary indicate that AMH may play an important role in ovarian folliculogenesis.
  • Recent advances in the physiological role of AMH has stimulated interest in the significance of AMH as a diagnostic marker and therapeutic agent for ovarian cancer.
  • Currently, AMH has been shown to be a circulating marker specifically for granulosa cell tumour (GCT).
  • Based on the physiological inhibitory role of AMH in the Mullerian ducts, it has been proposed that AMH may inhibit epithelial ovarian cancer cell both in vitro and in vivo.
  • These observations will be the basis for future research aiming to investigate the possible clinical role of AMH as neo-adjuvant, or most probably adjuvant, therapy for ovarian cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Glycoproteins / physiology. Glycoproteins / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / physiopathology. Testicular Hormones / physiology. Testicular Hormones / therapeutic use
  • [MeSH-minor] Anti-Mullerian Hormone. Biomarkers, Tumor / blood. Female. Humans

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17213257.001).
  • [ISSN] 1355-4786
  • [Journal-full-title] Human reproduction update
  • [ISO-abbreviation] Hum. Reprod. Update
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Testicular Hormones; 80497-65-0 / Anti-Mullerian Hormone
  • [Number-of-references] 61
  •  go-up   go-down


21. Yang L, He J, Huang S, Zhang X, Bian Y, He N, Zhang H, Xie J: Activation of hedgehog signaling is not a frequent event in ovarian cancers. Mol Cancer; 2009 Nov 27;8:112
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of hedgehog signaling is not a frequent event in ovarian cancers.
  • The hedgehog (Hh) signaling pathway regulates many processes of development and tissue homeostasis.
  • Activation of hedgehog signaling has been reported in about 30% of human cancer including ovarian cancer.
  • Inhibition of hedgehog signaling has been pursued as an effective strategy for cancer treatment including an ongoing phase II clinical trial in ovarian cancer.
  • However, the rate of hedgehog signaling activation in ovarian cancer was reported differently by different groups.
  • To predict the successful for future clinical trials of hedgehog signaling inhibitors in ovarian cancer, we assessed hedgehog pathway activation in 34 ovarian epithelial tumor specimens through analyses of target gene expression by in-situ hybridization, immunohistochemistry, RT-PCR and real-time PCR.
  • In contrast to previous reports, we only detected a small proportion of ovarian cancers with hedgehog target gene expression, suggesting that identification of the tumors with activated hedgehog signaling activation will facilitate chemotherapy with hedgehog signaling inhibitors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1980 Oct 30;287(5785):795-801 [6776413.001]
  • [Cites] Breast Cancer Res. 2005;7(3):86-95 [15987436.001]
  • [Cites] Nat Rev Drug Discov. 2006 Dec;5(12):1026-33 [17139287.001]
  • [Cites] J Pathol. 2007 Oct;213(2):131-9 [17724792.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3768-76 [18559595.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2008 Jul;40(7):670-80 [18604459.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1164-72 [19726763.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7659-66 [19047091.001]
  • [Cites] Dev Cell. 2008 Dec;15(6):801-12 [19081070.001]
  • [Cites] Carcinogenesis. 2009 Jan;30(1):131-40 [19028702.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:2089-102 [19273186.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Curr Opin Oncol. 2009 Sep;21(5):412-9 [19553815.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • (PMID = 19943941.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA94160
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2787497
  •  go-up   go-down


22. Sadarangani A, Kato S, Espinoza N, Lange S, Llados C, Espinosa M, Villalón M, Lipkowitz S, Cuello M, Owen GI: TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis; 2007 Jan;12(1):73-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer of the reproductive tract encompasses malignancies of the uterine corpus, cervix, ovary, Fallopian tube, among others and accounts for 15% of female cancer mortalities.
  • Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) mediates apoptosis by binding to death receptors and offers a promising cancer treatment.
  • The goal of this study was to investigate and characterize the effect of TRAIL in endometrial cancer cell lines and normal (non-cancerous) epithelial cells of endometrial origin.
  • We also examined the effect of TRAIL in other primary cultured cancers and normal cells of the human female reproductive tract and evaluated if TRAIL mediated apoptosis correlated with death receptors and decoy receptors 1 and 2.Herein, we demonstrate that TRAIL at concentrations which kill cancerous cells, does not mediate apoptosis or alter cell viability in normal human endometrium, ovary, cervix or Fallopian tube.
  • These results suggest that TRAIL may be an effective treatment for endometrial cancer and other female reproductive cancers, with minimal secondary effects on healthy tissue.
  • [MeSH-major] Apoptosis / drug effects. Genital Neoplasms, Female / drug therapy. Genital Neoplasms, Female / pathology. Genitalia, Female / drug effects. TNF-Related Apoptosis-Inducing Ligand / pharmacology
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Cells, Cultured. DNA, Complementary / genetics. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Endometrial Neoplasms / physiopathology. Endometrium / cytology. Endometrium / drug effects. Endometrium / physiology. Female. Humans. Receptors, TNF-Related Apoptosis-Inducing Ligand / genetics. Receptors, TNF-Related Apoptosis-Inducing Ligand / physiology. Recombinant Proteins / pharmacology. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Apoptosis. 2007 Feb;12(2):463
  • (PMID = 17136491.001).
  • [ISSN] 1360-8185
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / GR071469
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Recombinant Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human
  •  go-up   go-down


23. Nicoletto MO, Padrini R, Palumbo M, Ziade A, Ragazzi RS, Pratesi G, Artioli G, De Cesare M, Zunino F: Intralesional topotecan in advanced ovarian cancer: a clinical report, based on a preclinical study. Oncol Rep; 2002 Nov-Dec;9(6):1351-4
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional topotecan in advanced ovarian cancer: a clinical report, based on a preclinical study.
  • The aim of this study was to evaluate the response of ovarian cancer to intralesionally administered topotecan.
  • Preliminary experiments were carried out in nude mice subcutaneously grafted with three different human ovarian carcinoma cells (A2780, IGROV/DDP and SKOV-3).
  • Topotecan was administered intravenously (i.v.: 10-15 mg/kg every 4th day for 4 times) or intralesionally (i.t.: single dose of 15-20 mg/kg) and tumor size changes/drug toxicity were evaluated.
  • The results indicate that the sensitivity of the three tumor models was different (rank: A2780 > IGROV/DDP > SKOV-3) but, for each tumor line, the pattern of response was similar after i.v. and i.t. administration.
  • The effects of intralesional topotecan administration were then assessed in a patient with an advanced, epithelial ovarian tumor (endometroid type, poorly differentiated histologic grade), already treated with cisplatin and paclitaxel.
  • The treatment (7.5 mg/m(2)) was repeated three times and, although drug plasma levels were in the range generally reported following i.v. administration and typical systemic toxicity occurred, no tumor regression was observed and the patient died 14 months later.
  • We conclude that the intralesional drug delivery is effective to achieve a rapid tumor shrinkage in large tumor lesions, but in the presence of drug resistance, either intrinsic or acquired, intratumor drug administration can not be recommended.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Topotecan / therapeutic use
  • [MeSH-minor] Animals. Biomarkers, Tumor / blood. Blood Platelets / metabolism. CA-125 Antigen / blood. Drug Evaluation, Preclinical. Fatal Outcome. Female. Humans. In Vitro Techniques. Injections, Intralesional. Mice. Mice, Nude. Middle Aged. Neutrophils / metabolism. Osteolysis / etiology. Transplantation, Heterologous. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12375047.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


24. Swierzko AS, Florczak K, Cedzyński M, Szemraj J, Wydra D, Bak-Romaniszyn L, Emerich J, Sułowska Z: Mannan-binding lectin (MBL) in women with tumours of the reproductive system. Cancer Immunol Immunother; 2007 Jul;56(7):959-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated mbl2 genotypes, MBL concentrations, and MBL-MASP-2 complex activity in patients with ovarian cancer.
  • The expression of both mbl2 and masp-2 genes were investigated in ovarian tissue sections.
  • MBL-specific mRNA expression was detected in several normal and malignant ovarian tissues, as well as in ovarian epithelial cell lines.
  • Intracellular staining with MBL-specific antibodies demonstrated the presence of MBL in ovarian cell lines, and in normal as well as malignant ovarian tissue sections.
  • In contrast, MASP-2-specific mRNA expression was detected only in the ovary tissues of patients with malignant disease.
  • No significant changes in MBL concentration during 3 months of chemotherapy were noticed.
  • MBL was detected in ascites and in the fluid of benign ovarian cysts.
  • Our findings may reflect anti-tumourigenic activity of MBL protein which might suggest potential therapeutic application.
  • However, it cannot be excluded that mbl-2 mutant alleles may be in linkage disequilibrium with an unidentified tumour susceptibility gene(s).
  • [MeSH-major] Mannose-Binding Lectin / metabolism. Ovarian Neoplasms / genetics. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Flow Cytometry. Gene Expression. Gene Expression Profiling. Genotype. Haplotypes. Humans. Immunohistochemistry. Mannose-Binding Protein-Associated Serine Proteases / analysis. Mannose-Binding Protein-Associated Serine Proteases / metabolism. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131120.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mannose-Binding Lectin; EC 3.4.21.- / MASP2 protein, human; EC 3.4.21.- / Mannose-Binding Protein-Associated Serine Proteases
  •  go-up   go-down






Advertisement